Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

Phase 3 Terminated 772 enrolled Biohaven Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compulsive disorder (OCD).

Timeline

Start: 2021-03-30
Primary completion: 2026-02-13
Completion: 2026-02-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Troriluzole	Peptide	280 mg	—

Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

Summary

Timeline

Drugs

Indications